Sinotau Pharmaceutical Group Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2005

Location

Beijing China

Primary Industry

Pharmaceuticals

About

Established in 2005 and based in Beijing, China, Sinotau Pharmaceutical Group operates as a biopharmaceutical company that provides targeted therapy and precision diagnostic radiopharmaceuticals. The company has molecular imaging bases in Jiangsu, Guangdong and Sichuan. It cooperates with over 300 hospitals, such as Biogen, Merck and abbvie, and the academic outreach team has more than 100 members. In 2017, the company established Jiangsu and Guangdong Branch. In December 2021, it obtained a radiation safety license and established Shanghai R&D Center. In July 2023, it raised over CNY 1.1 billion in series E funding from Beijing GAGE Capital Management Company Ltd. and CCT Fund Management, etc. The company's product pipelines are divided into two series, which include the radiopharmaceuticals field and the biopharmaceuticals field. The radiopharmaceuticals field focuses on the development of antibody biologics, and can treat patients with tumors, neurodegenerative diseases and autoimmune diseases. The species of the biopharmaceuticals field involved in 18F, 13C and 14C series nuclides. In addition, the company engages in academic promotion through various ways, including public numbers (Hexing Liaowang), literature publication, journal submission, expert collaboration, academic seminar salon, summit forum and clinical trial data interpretation.

Current Investors

Qiming Venture Partners, 3E Bioventures Capital, Wuming Investment

Request a demo to show more

Primary Industry

Pharmaceuticals

Sub Industries

Biopharmaceuticals, Oncology/Cancer Treatment, Pharmaceutical Research & Development

Website

www.sinotau.com

Verticals

Manufacturing

Company Stage

Series E

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.